{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:46:38Z","timestamp":1794440798023,"version":"4.9.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["HT9425-24-1-0932"],"award-info":[{"award-number":["HT9425-24-1-0932"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["2P20GM121293"],"award-info":[{"award-number":["2P20GM121293"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008231","name":"Arkansas Biosciences Institute","doi-asserted-by":"publisher","award":["ABIRC4426"],"award-info":[{"award-number":["ABIRC4426"]}],"id":[{"id":"10.13039\/100008231","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Epigenetics & Chromatin"],"DOI":"10.1186\/s13072-025-00610-9","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T14:36:39Z","timestamp":1752503799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Epigenetic regulation of MED12: a key contributor to the leukemic chromatin landscape and transcriptional dysregulation"],"prefix":"10.1186","volume":"18","author":[{"given":"Arundhati","family":"Chavan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassidy","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whit","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6555-3031","authenticated-orcid":false,"given":"Samrat Roy","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"610_CR1","unstructured":"Swerdlow SH et al. (Lyon: IARC, 2008)."},{"key":"610_CR2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.exphem.2015.05.009","volume":"43","author":"A Eriksson","year":"2015","unstructured":"Eriksson A, Lennartsson A, Lehmann S. Epigenetic aberrations in acute myeloid leukemia: early key events during leukemogenesis. Exp Hematol. 2015;43:609\u201324. https:\/\/doi.org\/10.1016\/j.exphem.2015.05.009. https:\/\/doi.org:.","journal-title":"Exp Hematol"},{"key":"610_CR3","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1111\/febs.13142","volume":"282","author":"P Mehdipour","year":"2015","unstructured":"Mehdipour P, Santoro F, Minucci S. Epigenetic alterations in acute myeloid leukemias. FEBS J. 2015;282:1786\u2013800.","journal-title":"FEBS J"},{"key":"610_CR4","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1182\/blood-2015-03-631606","volume":"126","author":"J Sperlazza","year":"2015","unstructured":"Sperlazza J, et al. Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation. Blood. 2015;126:1462\u201372. https:\/\/doi.org\/10.1182\/blood-2015-03-631606.","journal-title":"Blood"},{"key":"610_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41586-022-05365-x","volume":"611","author":"J Xu","year":"2022","unstructured":"Xu J, et al. Subtype-specific 3D genome alteration in acute myeloid leukaemia. Nature. 2022;611:387\u201398.","journal-title":"Nature"},{"key":"610_CR6","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/cas.16069","volume":"115","author":"B Frett","year":"2024","unstructured":"Frett B, et al. Enhancer-activated RET confers protection against oxidative stress to KMT2A-rearranged acute myeloid leukemia. Cancer Sci. 2024;115:963\u201373. https:\/\/doi.org\/10.1111\/cas.16069.","journal-title":"Cancer Sci"},{"key":"610_CR7","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41580-022-00498-3","volume":"23","author":"WF Richter","year":"2022","unstructured":"Richter WF, Nayak S, Iwasa J, Taatjes DJ. The mediator complex as a master regulator of transcription by RNA polymerase II. Nat Rev Mol Cell Biol. 2022;23:732\u201349. https:\/\/doi.org\/10.1038\/s41580-022-00498-3.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"610_CR8","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/nature09380","volume":"467","author":"MH Kagey","year":"2010","unstructured":"Kagey MH, et al. Mediator and cohesin connect gene expression and chromatin architecture. Nature. 2010;467:430\u20135. https:\/\/doi.org\/10.1038\/nature09380.","journal-title":"Nature"},{"key":"610_CR9","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.tcb.2017.07.001","volume":"27","author":"C Jeronimo","year":"2017","unstructured":"Jeronimo C, Robert F. The mediator complex: at the Nexus of RNA polymerase II transcription. Trends Cell Biol. 2017;27:765\u201383. https:\/\/doi.org\/10.1016\/j.tcb.2017.07.001. https:\/\/doi.org:.","journal-title":"Trends Cell Biol"},{"key":"610_CR10","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1093\/nar\/gkn349","volume":"36","author":"HM Bourbon","year":"2008","unstructured":"Bourbon HM. Comparative genomics supports a deep evolutionary origin for the large, four-module transcriptional mediator complex. Nucleic Acids Res. 2008;36:3993\u20134008. https:\/\/doi.org\/10.1093\/nar\/gkn349.","journal-title":"Nucleic Acids Res"},{"key":"610_CR11","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.cell.2013.04.048","volume":"153","author":"MD Galbraith","year":"2013","unstructured":"Galbraith MD, et al. HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia. Cell. 2013;153:1327\u201339.","journal-title":"Cell"},{"key":"610_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1101\/gad.1767009","volume":"23","author":"MT Knuesel","year":"2009","unstructured":"Knuesel MT, Meyer KD, Bernecky C, Taatjes DJ. The human CDK8 subcomplex is a molecular switch that controls mediator coactivator function. Genes Dev. 2009;23:439\u201351. https:\/\/doi.org\/10.1101\/gad.1767009.","journal-title":"Genes Dev"},{"key":"610_CR13","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.stem.2016.08.004","volume":"19","author":"B Aranda-Orgilles","year":"2016","unstructured":"Aranda-Orgilles B, et al. MED12 regulates HSC-Specific enhancers independently of mediator kinase activity to control hematopoiesis. Cell Stem Cell. 2016;19:784\u201399. https:\/\/doi.org\/10.1016\/j.stem.2016.08.004. https:\/\/doi.org:.","journal-title":"Cell Stem Cell"},{"key":"610_CR14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.stem.2016.11.012","volume":"19","author":"S Borikar","year":"2016","unstructured":"Borikar S, Trowbridge JJ. The mediator of hematopoietic stem cell homeostasis. Cell Stem Cell. 2016;19:677\u20138. https:\/\/doi.org\/10.1016\/j.stem.2016.11.012. https:\/\/doi.org:.","journal-title":"Cell Stem Cell"},{"key":"610_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s00018-021-04056-6","volume":"79","author":"S Srivastava","year":"2022","unstructured":"Srivastava S, et al. MED12 is overexpressed in glioblastoma patients and serves as an oncogene by targeting the VDR\/BCL6\/p53 axis. Cell Mol Life Sci. 2022;79:104. https:\/\/doi.org\/10.1007\/s00018-021-04056-6.","journal-title":"Cell Mol Life Sci"},{"key":"610_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1530\/ERC-14-0171","volume":"21","author":"D Adler","year":"2014","unstructured":"Adler D, et al. MED12 overexpression is a frequent event in castration-resistant prostate cancer. Endocrine-related Cancer. 2014;21:663\u201375. https:\/\/doi.org\/10.1530\/ERC-14-0171.","journal-title":"Endocrine-related Cancer"},{"key":"610_CR17","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1002\/ijc.27424","volume":"131","author":"DN Markowski","year":"2012","unstructured":"Markowski DN, et al. MED12 mutations in uterine fibroids\u2014their relationship to cytogenetic subgroups. Int J Cancer. 2012;131:1528\u201336.","journal-title":"Int J Cancer"},{"key":"610_CR18","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40:850\u2013e864859. https:\/\/doi.org\/10.1016\/j.ccell.2022.07.002. https:\/\/doi.org:.","journal-title":"Cancer Cell"},{"key":"610_CR19","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","volume":"32","author":"AS Gamis","year":"2014","unstructured":"Gamis AS, et al. Gemtuzumab Ozogamicin in children and adolescents with de Novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III children\u2019s oncology group trial AAML0531. J Clin Oncol. 2014;32:3021\u201332.","journal-title":"J Clin Oncol"},{"key":"610_CR20","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/cncr.26190","volume":"118","author":"TM Cooper","year":"2012","unstructured":"Cooper TM, et al. AAML03P1, a pilot study of the safety of Gemtuzumab Ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the children\u2019s oncology group. Cancer. 2012;118:761\u20139.","journal-title":"Cancer"},{"key":"610_CR21","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","volume":"105","author":"R Aplenc","year":"2020","unstructured":"Aplenc R, et al. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the children\u2019s oncology group. Haematologica. 2020;105:1879.","journal-title":"Haematologica"},{"key":"610_CR22","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.celrep.2018.12.098","volume":"26","author":"G Yi","year":"2019","unstructured":"Yi G, et al. Chromatin-based classification of genetically heterogeneous AMLs into two distinct subtypes with diverse stemness phenotypes. Cell Rep. 2019;26:1059\u201369.","journal-title":"Cell Rep"},{"key":"610_CR23","doi-asserted-by":"publisher","first-page":"W247","DOI":"10.1093\/nar\/gkp464","volume":"37","author":"F Zambelli","year":"2009","unstructured":"Zambelli F, Pesole G, Pavesi G. Pscan: finding over-represented transcription factor binding site motifs in sequences from co-regulated or co-expressed genes. Nucleic Acids Res. 2009;37:W247\u2013252. https:\/\/doi.org\/10.1093\/nar\/gkp464.","journal-title":"Nucleic Acids Res"},{"key":"610_CR24","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/nature14465","volume":"523","author":"MD Schultz","year":"2015","unstructured":"Schultz MD, et al. Human body epigenome maps reveal noncanonical DNA methylation variation. Nature. 2015;523:212\u20136. https:\/\/doi.org\/10.1038\/nature14465.","journal-title":"Nature"},{"key":"610_CR25","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.trecan.2020.02.007","volume":"6","author":"J Smith","year":"2020","unstructured":"Smith J, Sen S, Weeks RJ, Eccles MR, Chatterjee A. Promoter DNA hypermethylation and Paradoxical gene activation. Trends Cancer. 2020;6:392\u2013406. https:\/\/doi.org\/10.1016\/j.trecan.2020.02.007.","journal-title":"Trends Cancer"},{"key":"610_CR26","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/cncr.32672","volume":"126","author":"S Zhang","year":"2020","unstructured":"Zhang S, O\u2019Regan R, Xu W. The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeutics. Cancer. 2020;126:939\u201348. https:\/\/doi.org\/10.1002\/cncr.32672.","journal-title":"Cancer"},{"key":"610_CR27","doi-asserted-by":"publisher","first-page":"19763","DOI":"10.1073\/pnas.1121120109","volume":"109","author":"H Zhou","year":"2012","unstructured":"Zhou H, et al. MED12 mutations link intellectual disability syndromes with dysregulated GLI3-dependent Sonic Hedgehog signaling. Proc Natl Acad Sci. 2012;109:19763\u20138. https:\/\/doi.org\/10.1073\/pnas.1121120109. https:\/\/doi.org.","journal-title":"Proc Natl Acad Sci"},{"key":"610_CR28","doi-asserted-by":"crossref","unstructured":"K\u00e4mpj\u00e4rvi K et al. Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. Oncotarget 6 (2015).","DOI":"10.18632\/oncotarget.2753"},{"key":"610_CR29","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.1158\/1538-7445.Am2023-4762","volume":"83","author":"SR Choudhury","year":"2023","unstructured":"Choudhury SR, Bhattacharya A. Abstract 4762: oncogenic over-expression of MED12 is epigenetically fostered in the core-binding factor subgroups of acute myeloid leukemia. Cancer Res. 2023;83:4762\u20134762. https:\/\/doi.org\/10.1158\/1538-7445.Am2023-4762.","journal-title":"Cancer Res"},{"key":"610_CR30","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.1038\/s41467-024-49811-y","volume":"15","author":"R Mulet-Lazaro","year":"2024","unstructured":"Mulet-Lazaro R, et al. Epigenetic alterations affecting hematopoietic regulatory networks as drivers of mixed myeloid\/lymphoid leukemia. Nat Commun. 2024;15:5693. https:\/\/doi.org\/10.1038\/s41467-024-49811-y.","journal-title":"Nat Commun"},{"key":"610_CR31","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1002\/1873-3468.14139","volume":"595","author":"P Srivastava","year":"2021","unstructured":"Srivastava P, Takii R, Okada M, Fujimoto M, Nakai A. MED12 interacts with the heat-shock transcription factor HSF1 and recruits CDK8 to promote the heat-shock response in mammalian cells. FEBS Lett. 2021;595:1933\u201348. https:\/\/doi.org\/10.1002\/1873-3468.14139.","journal-title":"FEBS Lett"},{"key":"610_CR32","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1093\/hmg\/ddx099","volume":"26","author":"LM Donnio","year":"2017","unstructured":"Donnio LM, et al. MED12-related XLID disorders are dose-dependent of immediate early genes (IEGs) expression. Hum Mol Genet. 2017;26:2062\u201375. https:\/\/doi.org\/10.1093\/hmg\/ddx099.","journal-title":"Hum Mol Genet"},{"key":"610_CR33","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1038\/leu.2014.124","volume":"28","author":"AP Im","year":"2014","unstructured":"Im AP, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia. 2014;28:1774\u201383. https:\/\/doi.org\/10.1038\/leu.2014.124.","journal-title":"Leukemia"},{"key":"610_CR34","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1074\/jbc.RA118.006795","volume":"294","author":"JE Sandoval","year":"2019","unstructured":"Sandoval JE, Huang YH, Muise A, Goodell MA, Reich NO. Mutations in the DNMT3A DNA methyltransferase in acute myeloid leukemia patients cause both loss and gain of function and differential regulation by protein partners. J Biol Chem. 2019;294:4898\u2013910. https:\/\/doi.org\/10.1074\/jbc.RA118.006795.","journal-title":"J Biol Chem"},{"key":"610_CR35","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1182\/blood-2021-148574","volume":"138","author":"S Roy Choudhury","year":"2021","unstructured":"Roy Choudhury S, et al. Epigenetically enhanced MED12L in ETO2-GLIS2 positive pediatric acute megakaryoblastic leukemia is associated with resistance to the CDK8 inhibitors. Blood. 2021;138:2208. https:\/\/doi.org\/10.1182\/blood-2021-148574.","journal-title":"Blood"},{"key":"610_CR36","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1073\/pnas.1917635117","volume":"117","author":"F Klatt","year":"2020","unstructured":"Klatt F, et al. A precisely positioned MED12 activation helix stimulates CDK8 kinase activity. Proc Natl Acad Sci U S A. 2020;117:2894\u2013905. https:\/\/doi.org\/10.1073\/pnas.1917635117.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Epigenetics & Chromatin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13072-025-00610-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13072-025-00610-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13072-025-00610-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T08:52:57Z","timestamp":1757235177000},"score":1,"resource":{"primary":{"URL":"https:\/\/epigeneticsandchromatin.biomedcentral.com\/articles\/10.1186\/s13072-025-00610-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["610"],"URL":"https:\/\/doi.org\/10.1186\/s13072-025-00610-9","relation":{},"ISSN":["1756-8935"],"issn-type":[{"value":"1756-8935","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"6 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: ESM has been updated.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Transcriptome (mRNA expression) data analysis was conducted on pAML specimens from consented patients enrolled in the TARGET-AML study (phs000465), with access granted via the Database of Genotypes and Phenotypes (dbGaP). Transcriptome and mutation data for adult AML samples were obtained from the BEAT AML 2.0 study through VIZOME. Data on DNase hypersensitivity, histone modifications, and DNA methylation for primary AML patients were accessed from the BLUEPRINT Epigenome Consortium.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read the final version of manuscript and consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}